positioning Simparica Trio for continued dominance. Guidance reflects foreign exchange headwinds of approximately $250 million to revenue and $50 million to adjusted net income. Zoetis reported Q4 ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsSteve Frank - IRKristin Peck - CEOWetteny Joseph ...

Zoetis, Inc. ZTS delivered fourth-quarter 2024 adjusted earnings (excluding one-time items) of $1.40 per share, which ...

Zoetis Inc (ZTS) reports robust financial performance with significant growth in companion animal products and strategic ...

During the fourth quarter, Zoetis observed major revenue growth in companion animal products, marking an 8% increase. This growth is attributed to notable products such as Simparica Trio ...

Zoetis said the U.S. Department of Agriculture's Center for Veterinary Biologics issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is ...

Coming up: In 2025, Zoetis is set to face more direct competition for some its flagship therapies, including Apoquel and Simparica Trio. It's not clear that rival Elanco's new entrants (Zenrelia ...

BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...

Q4 2024 Management View CEO Kristin Peck highlighted Zoetis delivered an excellent 2024, achieving double-digit operational revenue growth of 11% and adjusted net income growth of 15%. U.S. and ...

as well as Zoetis’ parasiticide products, such as Simparica and the Simparica Trio. Livestock product sales were flat year over year on a reported basis and grew 6% operationally to $477 million.

Librela for dogs and Solensia for cats, dermatology products like Apoquel and Cytopoint, as well as Zoetis’ parasiticide products, such as Simparica and the Simparica Trio.